Hantz Financial Services Inc. Increases Stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Hantz Financial Services Inc. boosted its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 87.2% in the 3rd quarter, HoldingsChannel.com reports. The institutional investor owned 73 shares of the biopharmaceutical company’s stock after buying an additional 34 shares during the quarter. Hantz Financial Services Inc.’s holdings in Regeneron Pharmaceuticals were worth $77,000 as of its most recent SEC filing.

Several other large investors have also bought and sold shares of REGN. SteelPeak Wealth LLC boosted its position in shares of Regeneron Pharmaceuticals by 173.0% during the second quarter. SteelPeak Wealth LLC now owns 1,092 shares of the biopharmaceutical company’s stock valued at $1,148,000 after purchasing an additional 692 shares in the last quarter. Mizuho Securities USA LLC lifted its position in Regeneron Pharmaceuticals by 625.5% during the third quarter. Mizuho Securities USA LLC now owns 59,341 shares of the biopharmaceutical company’s stock valued at $62,382,000 after buying an additional 51,162 shares during the period. Tri Locum Partners LP boosted its holdings in shares of Regeneron Pharmaceuticals by 104.5% during the 2nd quarter. Tri Locum Partners LP now owns 17,516 shares of the biopharmaceutical company’s stock valued at $18,410,000 after buying an additional 8,949 shares in the last quarter. Simplify Asset Management Inc. grew its position in shares of Regeneron Pharmaceuticals by 50.8% in the 3rd quarter. Simplify Asset Management Inc. now owns 9,591 shares of the biopharmaceutical company’s stock worth $10,082,000 after buying an additional 3,231 shares during the period. Finally, Catalytic Wealth RIA LLC purchased a new stake in shares of Regeneron Pharmaceuticals in the 3rd quarter worth about $1,334,000. 83.31% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Several equities research analysts recently commented on the stock. Leerink Partners reissued a “market perform” rating and set a $1,077.00 price objective (down previously from $1,175.00) on shares of Regeneron Pharmaceuticals in a research note on Tuesday, September 24th. JPMorgan Chase & Co. dropped their price target on Regeneron Pharmaceuticals from $1,200.00 to $1,150.00 and set an “overweight” rating on the stock in a research report on Thursday, October 24th. Evercore ISI reduced their price objective on Regeneron Pharmaceuticals from $1,250.00 to $1,175.00 and set an “outperform” rating for the company in a research report on Thursday, October 24th. Wells Fargo & Company dropped their target price on Regeneron Pharmaceuticals from $1,200.00 to $1,050.00 and set an “overweight” rating on the stock in a report on Tuesday, October 22nd. Finally, Cantor Fitzgerald restated a “neutral” rating and set a $1,015.00 price target on shares of Regeneron Pharmaceuticals in a report on Wednesday, October 23rd. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating, seventeen have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, Regeneron Pharmaceuticals currently has a consensus rating of “Moderate Buy” and an average target price of $1,107.29.

Regeneron Pharmaceuticals Price Performance

NASDAQ REGN opened at $762.34 on Tuesday. The company has a debt-to-equity ratio of 0.09, a current ratio of 5.28 and a quick ratio of 4.46. Regeneron Pharmaceuticals, Inc. has a 1-year low of $735.95 and a 1-year high of $1,211.20. The stock has a market capitalization of $83.77 billion, a price-to-earnings ratio of 18.87, a PEG ratio of 2.89 and a beta of 0.15. The business’s fifty day moving average price is $905.64 and its 200-day moving average price is $1,019.64.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.